Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

US President Donald Trump has signalled plans to impose a 25% tariff on car imports, along with similar or higher levies on ...

Britain will investigate the long-term effects of vaping on children as young as eight in a decade-long study of their health ...

Woodside Energy has held talks with several potential buyers of stakes in its Louisiana liquefied natural gas plant, ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive growth. The number of Americans taking GLP-1s for weight loss rose more ...

Background Intravenous iron therapy with ferric derisomaltose (FDI) has been shown to improve outcomes in patients with heart ...

Eli Lilly rose 3.3% after the drugmaker showed how demand for ... and the Nasdaq composite rose 99.66 points to 19,791.99. In ...

With a market cap of $799.5 billion, Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading global pharmaceutical firm renowned for its innovative contributions to healthcare.

Wall Street drifted through a mixed day of trading as rising fashion and cigarette stocks worked against drops for Ford Motor and Qualcomm. The S&P 500 rose 0.4% Thursday following ...